SNIPR Biome ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sniprbiome.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli PreTransplant
Phase 1
Recruiting
- Conditions
- E Coli InfectionsAllogenic Transplant Patients
- Interventions
- Biological: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coliOther: Placebo 10 mL
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- SNIPR Biome Aps.
- Target Recruit Count
- 24
- Registration Number
- NCT06938867
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
Phase 1
Completed
- Conditions
- E.Coli InfectionsBloodstream Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- SNIPR Biome Aps.
- Target Recruit Count
- 36
- Registration Number
- NCT05277350
- Locations
- 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
News
No news found